Ascendiant Capital Markets Cuts Aemetis (NASDAQ:AMTX) Price Target to $19.00

Aemetis (NASDAQ:AMTX) had its target price reduced by Ascendiant Capital Markets from $20.00 to $19.00 in a research report released on Tuesday, MarketBeat.com reports. They currently have a buy rating on the specialty chemicals company’s stock.

AMTX has been the subject of a number of other reports. UBS Group decreased their price objective on Aemetis from $8.25 to $7.75 and set a buy rating for the company in a research note on Monday, August 19th. HC Wainwright restated a buy rating and issued a $28.00 price target on shares of Aemetis in a report on Friday, August 2nd. StockNews.com upgraded shares of Aemetis to a sell rating in a research note on Wednesday, July 31st. Finally, Truist Financial reissued a hold rating and set a $3.50 target price (down previously from $4.00) on shares of Aemetis in a research report on Wednesday, July 31st. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of Moderate Buy and a consensus price target of $12.95.

Aemetis Price Performance

Shares of Aemetis stock opened at $2.22 on Tuesday. The stock has a market cap of $98.56 million, a price-to-earnings ratio of -1.90 and a beta of 1.31. The firm’s 50-day moving average is $2.95 and its two-hundred day moving average is $3.54. Aemetis has a 1 year low of $2.10 and a 1 year high of $7.03.

Aemetis (NASDAQ:AMTX) last released its quarterly earnings data on Thursday, August 1st. The specialty chemicals company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.25). The firm had revenue of $66.56 million for the quarter, compared to analysts’ expectations of $75.37 million. During the same quarter in the previous year, the company posted ($0.68) EPS. On average, equities analysts expect that Aemetis will post -2.19 earnings per share for the current year.

Hedge Funds Weigh In On Aemetis

Several hedge funds and other institutional investors have recently modified their holdings of AMTX. Susquehanna Fundamental Investments LLC grew its position in Aemetis by 287.4% during the 2nd quarter. Susquehanna Fundamental Investments LLC now owns 126,078 shares of the specialty chemicals company’s stock worth $379,000 after purchasing an additional 93,536 shares during the last quarter. Hutchinson Capital Management CA purchased a new stake in shares of Aemetis during the second quarter valued at $70,000. Rhumbline Advisers increased its position in shares of Aemetis by 2,837.1% in the 2nd quarter. Rhumbline Advisers now owns 52,309 shares of the specialty chemicals company’s stock valued at $157,000 after acquiring an additional 50,528 shares during the period. Bank of New York Mellon Corp purchased a new position in Aemetis in the 2nd quarter worth $306,000. Finally, State Board of Administration of Florida Retirement System acquired a new stake in Aemetis during the 1st quarter worth about $84,000. 27.02% of the stock is owned by hedge funds and other institutional investors.

Aemetis Company Profile

Aemetis, Inc operates as a renewable natural gas and renewable fuels company. It operates through three segments: California Ethanol, California Dairy Renewable Natural Gas, and India Biodiesel. The company focuses on the operation, acquisition, development, and commercialization of technologies to produce low and negative carbon intensity renewable fuels that replace fossil-based products.